Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize Management
    Release Date:
    Partner: Beijing Guangda Precision Medicine Research Center
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology China
    Optimizing Antimicrobial Stewardship Program in Saudi Arabia
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology Saudi Arabia
    PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Pediatric pneumococcal carriage and serotype distribution surveillance: prospective studies in South-East Asia, 2025-2026
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
    Advancing Health Care Professionals’ knowledge and understanding of adult and maternal vaccination against respiratory infection
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Israel, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Slovenia, Ukraine
    Review and analysis of serotype distribution and burden of pneumococcal disease in children younger than 5 years – Post vac era
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Burkina Faso, Congo, The Democratic Republic, Cote D'ivoire, Ethiopia, Ghana, Mozambique, Pakistan, Senegal, Sudan, Tanzania, United Republic of
    The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China, Hong Kong
    COVID-19 Disease Burden on the High Risk Population
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines All
    New Research Areas to Improve Diagnosis and Treatment of Inflammatory Bowel Disease
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology USA
    Education on Actionable Biomarker and Genetic Testing in Cancer for the Advanced Practice Provider (APP)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Unmet Needs and Emerging Data in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Enhancing HCPs’ Preparedness: Maternal Immunization Knowledge Updates
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Real-World Clinical Outcomes Among Adult and Adolescent Patients with Severe Alopecia Areata Receiving Ritlecitinib in China
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic Bladder
    Release Date:
    Review Process: Pfizer Internal
    Translation: Japanese (link)
    Education Internal Medicine Japan
    Interventional Research Studies with Elranatamab
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology All
    Research in Ulcerative Colitis (UC) 2024
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology Brazil, India, Mexico, Saudi Arabia, Taiwan, Turkey
    Advances in the Management of Ulcerative Colitis (UC)
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    Research in Ulcerative Colitis (UC) 2024
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology USA
    BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Translation: Japanese (link)
    Education Oncology Japan
    Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
    Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease All
    Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
    Release Date:
    Partner: Sumitomo Pharma
    Review Process: Pfizer Internal
    Education Oncology USA